Chugai’s Q1 Sales Drop 24% on End of Ronapreve Govt Purchase and Generic Competition

Chugai Pharmaceutical’s group sales for the first quarter of 2024 dropped by two digits over the year primarily due to the end of deliveries of the COVID-19 treatment Ronapreve (casirivimab + imdevimab) to the Japanese government, price cuts, and generic...read more